MAPS Bulletin Autumn 1990: Vol. 01, No. 3 What and Who is MAPS?

Download this entire issue or browse individual articles by title below.

	What and Who is MAPS?	Rick Doblin, Ph.D.
	The Two Functions of MAPS	Rick Doblin, Ph.D.
	Thoughts About the Ethics of Animal Research	Rick Doblin, Ph.D.
	MDMA Neurotoxicity Overview	Rick Doblin, Ph.D.
	Preliminary Findings from Primate Neurotoxicity Studies	Rick Doblin, Ph.D.
	Dr. Nichols Confirms that Prozac Blocks MDMA Neurotoxicity	Rick Doblin, Ph.D.
	Requested - Subjective Reports of the Prozac / MDMA Combinations	Rick Doblin, Ph.D.
	Findings From the Two NIDA-Funded MDMA Human Studies	Rick Doblin, Ph.D.
	A Call for Volunteers for the Johns Hopkins MDMA Human Neurotoxicity Study	Rick Doblin, Ph.D.
	Update on Swiss Psychedelic Research	Rick Doblin, Ph.D.
	Unsuccessful MAPS Attempts at Collaborative Research	Rick Doblin, Ph.D.
	Swiss Psychedelic Usage Halted - Resumption Possible But Not Certain	Rick Doblin, Ph.D.
	New Opportunities for MDMA Research in Czechoslovakia	Rick Doblin, Ph.D.
	The MAPS International Research Methodology Conference	Rick Doblin, Ph.D.
	Pharmaceutical Companies Study the Market For Psychedelics	Rick Doblin, Ph.D.
	MAPS' Research Agenda and Financial Requests	Rick Doblin, Ph.D.